Business Wire

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
Business Wire

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

- CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers - Clasp's pHLAre™ ...
Yahoo Finance

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting

CAMBRIDGE, MA. & ROCKVILLE, MD., November 07, 2024--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation TCEs, today ...
Yahoo Finance

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

- Clasp's pHLAre™ platform is optimized for tumor-specific antigens, with the potential to yield safer and more effective precision immunotherapies - Preclinical data presented at the 2025 American ...